Skip to main content

Table 1 Baseline characteristics of the study population

From: The temporal dynamics of plasma fractalkine levels in ischemic stroke: association with clinical severity and outcome

Parameters

Total stroke patients (n = 55)

Favorable outcome (n = 33)

Unfavorable outcome (n = 22)

Control (n = 32)

Pvalue

Gender

    

0.014

Female

25 (45%)

10 (30%)

15 (68%)

18 (56%)

 

Male

30 (55%)

23 (79%)

7 (32%)

14 (44%)

 

Age (Years, Median) (25th to 75th percentiles)

69 (62 to 77 )

68 (62 to 74)

76,5 (57,75 to 85)

71 (61,25 to 75,75)

0.277

Etiology

    

0.258

Large artery atherosclerosis

8 (15%)

3 (9%)

5 (23%)

-

 

Cardioembolism

14 (25%)

7 (21%)

7 (32%)

-

 

Small vessel occlusion

13 (24%)

10 (30%)

3 (14%)

-

 

Undetermined

20 (36%)

13 (39%)

7 (32%)

-

 

Stroke severity

    

0.001

Mild

28 (51%)

23 (70%)

5 (23%)

-

 

Moderate/severe

27 (49%)

10 (30%)

17 (77%)

-

 

SBP (mmHg, Median) (25th to 75th percentiles)

135 (130 to 143)

135 (130 to 142)

135 (129 to 145,25)

130 (120 to 140)

0.453

DBP (mmHg, Median) (25th to 75th percentiles)

80 (70 to 86)

80 (70 to 88,5)

80 (70 to 85)

80 (70 to 90)

0.344

Hypertension

34 (62%)

19 (58%)

15 (68%)

24 (75%)

0.325

Nicotine consumption

10 (18%)

7 (21%)

3 (14%)

6 (19%)

0.495

Dyslipoproteinemia

19 (35%)

12 (36%)

7 (32%)

17 (53%)

0.224

Diabetes mellitus

6 (11%)

3 (9%)

3 (14%)

4 (13%)

0.853

i.v. rtPA

8 (15%)

3 (9%)

5 (23%)

-

0.160

  1. Kruskal-Wallis test or Chi-square compared the groups (favorable, unfavorable strokes and controls). P<0.05 is considered significant. DBP, diastolic blood pressure; i.v. rtPA, intravenous reverse tissue-type plasminogen activator; SBP, systolic blood pressure,